Clinical Trial Update: A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of DS-2325a in Netherton syndrome has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Netherton Syndrome

Drugs mentioned

• DS-2325a

Snippet

Sponsor: Daiichi Sankyo | Conditions: Netherton Syndrome | Phase 1, Phase 2 | Status: TERMINATED